Litigation Details for Salix Pharmaceuticals Ltd. v. Sun Pharmaceuticals Industries Ltd. (D. Del. 2019)

Salix Pharmaceuticals Ltd. v. Sun Pharmaceuticals Industries Ltd. (D. Del. 2019)

Docket	1:19-cv-00734	Date Filed	2019-04-24
Court	District Court, D. Delaware	Date Terminated	2020-09-25
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Both	Referred To
Parties	ALFASIGMA S.P.A.
Patents	10,314,828; 10,335,397; 10,456,384; 10,703,763; 10,709,694; 10,765,667; 7,045,620; 7,612,199; 7,902,206; 7,906,542; 7,915,275; 7,928,115; 8,158,644; 8,158,781; 8,193,196; 8,309,569; 8,518,949; 8,642,573; 8,741,904; 8,829,017; 8,835,452; 8,853,231; 8,946,252; 8,969,398; 9,271,968; 9,421,195; 9,629,828
Attorneys	Elizabeth E. Grden
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Salix Pharmaceuticals Ltd. v. Sun Pharmaceuticals Industries Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-24				External link to document
2019-04-24	1	Complaint	United States Patent Nos. 7,045,620 (the “’620 patent”); 7,612,199 (the “’199 patent”); 7,902,206 (the…infringed one or more claims of United States Patent Nos. 7,045,620; 7,612,199; 7,902,206; 7,906,542; 8,158,644…infringe one or more claims of United States Patent Nos. 7,045,620; 7,612,199; 7,902,206; 7,906,542; 8,158,… C. A judgment that United States Patent Nos. 7,045,620; 7,612,199; 7,902,206; 7,906,542; 8,158,644…to the expiration date of United States Patent Nos. 7,045,620; 7,612,199; 7,902,206; 7,906,542; 8,158,644	External link to document
2019-04-24	118		the Invalidity of U.S. Patent Nos. 8,642,573; 8,969,398; 9,421,195; 10,335,397; and 10,709,694 4. Opening…Bergstrom, Ph.D. Regarding the Invalidity of U.S. Patent No. 7,906,542 2. Opening Expert of Michael J. Zaworotko…Zaworotko, Ph.D. Regarding the Invalidity of U.S. Patent Nos. 7,045,620; 7,612,199; 7,902,206; and 7,906,542… 25 September 2020 1:19-cv-00734 835 Patent - Abbreviated New Drug Application(ANDA) Both	External link to document
2019-04-24	138		Ph.D. Regarding the Invalidity of U.S. Patent Nos. 7,045,620; 7,612,199; 7,902,206; and 7,906,542 (3)…Bergstrom, Ph.D. Regarding the Invalidity of U.S. Patent No. 7,906,542 (7) Responsive Expert Report of Richard…Regarding Noninfringement of Claims 9 and 10 of U.S. Patent No. 7,906,542 filed by Norwich Pharmaceuticals … 25 September 2020 1:19-cv-00734 835 Patent - Abbreviated New Drug Application(ANDA) Both	External link to document
2019-04-24	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,045,620 ;7,612,199 ;7,902,206… 25 September 2020 1:19-cv-00734 835 Patent - Abbreviated New Drug Application(ANDA) Both	External link to document

Litigation Summary and Analysis: Salix Pharmaceuticals Ltd. v. Sun Pharmaceuticals Industries Ltd. | Case No. 1:19-cv-00734

Last updated: February 19, 2026

Case Overview

Salix Pharmaceuticals Ltd. filed a patent infringement lawsuit against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware. The case, numbered 1:19-cv-00734, commenced in 2019. The primary issue involves allegations that Sun Pharmaceuticals' generic version of Xifaxan (rifaximin) infringes upon patents held by Salix.

Patent and Product Details

• Patents involved: Salix alleges infringement of U.S. Patent Nos. 9,734,170 and 9,551,543, both covering formulations and methods of treatment associated with Xifaxan.
• Product accused: Sun's generic rifaximin product, intended for irritable bowel syndrome (IBS) with diarrhea.
• Market exclusivity: Salix holds exclusive rights until at least 2024, based on patent expiry dates and patent term adjustments.

Timeline and Proceedings

2019: Complaint Filing

Salix initiates suit alleging patent infringement. The complaint claims Sun's generic infringes the '170 and '543 patents.

2020-2021: Litigation Activities

• Preliminary motions: Sun files motions to dismiss or stay proceedings based on patent validity and Hatch-Waxman provisions.
• Discovery phase: Both parties exchange documents and prepare for trial, with incidents of dispute over patent claim interpretation.

2022: Patent Trial and Potential Resolution

• Court's Markman hearing defines the scope of patent claims.
• Parties engage in settlement discussions; patent term extensions and potential generic launch timing are central issues.

2023: Current Status

• The case remains active. No final judgment or settlement has been publicly disclosed.
• Both sides have filed summary judgment motions focusing on patent validity and infringement.

Key Legal Issues

Patent Validity

Sun Pharmaceuticals challenges the validity of the patents, citing prior art, obviousness, and patent term considerations.

Infringement

Salix asserts that Sun's generic infringes upon claims related to composition and method of use.

Remedy

Salix seeks injunctive relief to prevent Sun’s product launch and monetary damages for past infringement.

Market and Policy Implications

• Generic entry delay influences market competition and drug pricing.
• Patent disputes in the pharmaceutical industry impact R&D investment and innovation incentives.
• The case reflects ongoing patent litigation strategies to defend exclusivity rights.

Key Data Points

Aspect	Details
Case number	1:19-cv-00734
Court jurisdiction	U.S. District Court, District of Delaware
Patents involved	U.S. Patent Nos. 9,734,170; 9,551,543
Infringing product	Sun Pharmaceuticals' generic rifaximin
Initiation date	2019
Patent expiry (approximate)	2024
Main legal challenges	Patent validity; infringement

Analysis

The litigation underscores the regulatory balancing act in pharmaceutical patent law. Challenges to patent validity focus on prior art and obviousness, common in Hatch-Waxman disputes. The outcome could influence the timing of generic entry, affecting price competition and supply stability.

The ongoing case exemplifies the strategic use of patent infringement lawsuits to extend market exclusivity. Since patent validity remains contested, resolution hinges on court findings or settlement negotiations.

Key Takeaways

• The case involves standard patent infringement claims relating to a blockbuster antibiotic.
• Disputes over patent validity are central; Sun's defenses include prior art and obviousness arguments.
• Market implications center on delay or facilitation of generic product launch.
• The plaintiff aims to maintain patent protections to preserve exclusivity and revenue.
• Resolution is pending, with potential for court-ordered injunction or licensing agreement.

FAQs

1. What patents are at the center of this litigation?
Salix claims infringement of U.S. Patent Nos. 9,734,170 and 9,551,543, covering drug formulation and treatment methods related to Xifaxan.

2. Why is Sun Pharmaceuticals challenging these patents?
Sun argues that the patents are invalid due to prior art references and obviousness, aiming to accelerate generic entry.

3. What are the potential outcomes?
The court may uphold the patents, resulting in injunctive relief, or find them invalid, paving the way for generic approval and launch.

4. How does this case affect market prices?
A ruling in favor of Salix could delay generic entry, maintaining higher drug prices. Conversely, invalidation might reduce prices post-approval.

5. When might a resolution occur?
No final decision has been announced. The case could reach resolution via trial, settlement, or summary judgment, likely within the next 1-2 years.

---

References

1. U.S. District Court. (2023). Salix Pharmaceuticals Ltd. v. Sun Pharmaceuticals Industries Ltd., Case No. 1:19-cv-00734.
2. U.S. Patent and Trademark Office. (2023). Patent Nos. 9,734,170 and 9,551,543.